Phathom Pharmaceuticals (PHAT) Non Operating Income (2018 - 2026)

Phathom Pharmaceuticals (PHAT) has 9 years of Non Operating Income data on file, last reported at -$14.9 million in Q1 2026.

• On a quarterly basis, Non Operating Income rose 3.63% year-over-year to -$14.9 million in Q1 2026; TTM through Mar 2026 was -$60.7 million, a 2.16% decrease from a year earlier, with the FY2025 full-year figure at -$61.3 million, down 7.74% from the prior year.
• Non Operating Income for Q1 2026 stood at -$14.9 million, up from -$15.2 million in the prior quarter.
• Over the last five years, Non Operating Income for PHAT reached as high as -$2.8 million in Q1 2022 and fell as low as -$15.9 million in Q2 2025.
• Historically, Non Operating Income has averaged -$11.3 million across 5 years, with a median of -$12.9 million in 2024.
• Across the five-year window, Non Operating Income plunged 350.69% in 2022 and rose 11.42% in 2023, its largest moves.
• Year by year, Non Operating Income stood at -$8.4 million in 2022, then declined by 15.35% to -$9.7 million in 2023, then sank by 55.07% to -$15.0 million in 2024, then retreated by 1.24% to -$15.2 million in 2025, then climbed by 2.16% to -$14.9 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$14.9 million in Q1 2026, -$15.2 million in Q4 2025, and -$14.7 million in Q3 2025.